Summit Therapeutics Inc. (SMMT) Down 5.7% — Time to Hit the Eject Button?
Summit Therapeutics Inc. (SMMT) is under pressure on Monday, currently trading at $14.60 on the NASDAQ, an $0.87 decline from the prior close of $15.47. The stock now sits roughly 50% below its 52-week high of $29.23, reached on April 21, 2026, and about 21% above the bottom of its 52-week range at $12.07. That leaves SMMT much closer to its lows than its highs, a sign of how much enthusiasm has drained from the name since the spring.
Volume stands at approximately 2.80 million shares with the session still open, roughly half the 90-day average of about 5.63 million. Today's decline is coming on measured participation rather than a rush for the exits.
Why Summit Therapeutics Inc. Price is Moving Lower
The most plausible driver is a company-specific "sell-the-news" reaction to clinical data that investors had largely already priced in. The trigger was a detailed presentation at ESMO. On October 25, Akeso reported that its China-only Phase III HARMONi-GI1 trial of ivonescimab showed median overall survival of 14.9 months versus 12.1 months for durvalumab plus chemotherapy. That works out to a 25% lower risk of death, with a hazard ratio of 0.75 and a p-value of 0.0031. On paper that is a clean win. The catch is timing. Summit had already disclosed the trial's positive survival result in an August 25 filing, so the ESMO presentation filled in the numbers rather than delivering the first signal of success. With the headline outcome already known for two months, the detailed readout gave holders an opportunity to take profits.
The broader tape points the same way. The SPDR S&P Biotech ETF (XBI) was up 1.10% at 10:30 a.m. ET, a sharp contrast to Summit's decline. Sector peers drifted only modestly lower, with Revolution Medicines, Inc. (RVMD) down 1.48% and Moderna, Inc. (MRNA) off 1.06%. A drop of more than 5% while Biotech broadly held up marks this as Summit's own story. The China-only nature of the HARMONi-GI1 data adds to the hesitation. Investors may want confirmation from Summit's U.S. development program before assigning full value to results generated in a single market.
Wall Street remains sharply divided on what the data is worth. On October 26, Bernstein maintained a Hold rating with an $11.90 price target, below where the stock is trading today. Stifel reiterated its Buy rating with a $38 target, well above current levels. That gap reflects a wide valuation debate rather than a direct cause of today's move. It also underscores how much of Summit's $12.37 billion market cap rests on future clinical and regulatory outcomes rather than current earnings. The company carries EPS of -$1.12 and a forward P/E of -13.79, figures that leave the valuation entirely dependent on the ivonescimab pipeline delivering.
What is the Summit Therapeutics Inc. Rating - Should I Sell?
Weiss Ratings assigns SMMT a D- rating. The rating was upgraded on 8/12/2025. Current recommendation is Sell. The upgrade lifted the stock off the very bottom of the scale, but a D- still signals that the risks outweigh the potential rewards in Weiss's framework. For a company whose valuation hinges almost entirely on one experimental drug, that caution is well grounded.
The clear strength is the balance sheet. Summit is rated Excellent on the Solvency Index, which indicates the company is not under near-term financial strain despite running costly late-stage oncology trials. For a clinical-stage biotech, that matters a great deal. Funding capacity determines whether a company can carry multiple Phase III programs through to regulatory decisions without forced dilution at a bad moment. Summit's solvency position gives it room to keep advancing ivonescimab across lung and colorectal cancer indications.
Where the picture deteriorates is in the operating and market-based dimensions. The Very Weak ratings on both the Growth Index and the Efficiency Index reflect the reality of a company without an established commercial revenue base. EPS of -$1.12 shows how far Summit remains from self-sustaining operations, and the negative forward P/E of -13.79 means investors are paying for a pipeline rather than profits. These ratings are unlikely to improve until ivonescimab moves from trial results to approved sales.
Shareholder experience tells a more mixed story. The Fair rating on the Total Return Index captures a stock that has given back about half its value from the April high of $29.23 but still trades well above its 52-week low of $12.07. The Weak Volatility Index is easier to explain. A trading range spanning more than $17 over the past year, along with today's sell-the-news decline on otherwise positive data, shows how violently this stock reacts to clinical headlines. Within the Health Care sector, Summit is on par with Moderna, Inc. (MRNA, D-), Revolution Medicines, Inc. (RVMD, D-), and Roivant Sciences Ltd. (ROIV, D-), while trailing Zoetis Inc. (ZTS, D). Zoetis is a profitable animal health company and carries a modestly better risk profile.
About Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT) is a Health Care company that focuses on the discovery, development, and commercialization of medicinal therapies built around patients, physicians, caregivers, and broader society. Founded in 2003 and headquartered in Miami, Florida, the company has staked its future on a single lead candidate, ivonescimab. The drug is a bispecific antibody that pairs PD-1 immune checkpoint blockade with anti-angiogenesis activity in one molecule. The design aims to combine the tumor-fighting effect of immunotherapy with the ability to choke off the blood supply tumors rely on to grow.
Summit's development program targets some of the largest markets in oncology. Ivonescimab combined with chemotherapy is in Phase III clinical trials for patients with epidermal growth factor receptor-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer. It is also being studied in first-line metastatic non-small cell lung cancer and in first-line unresectable metastatic colorectal cancer. Akeso runs a parallel development effort in China, including the HARMONi-GI1 study, which gives Summit a second stream of clinical evidence alongside its own trials.
Summit's commercial reach spans the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa. Its main competitive advantage is ivonescimab's dual mechanism, which positions it as a potential challenger to established PD-1 and PD-L1 therapies in lung cancer and beyond. That advantage remains largely theoretical until regulators in Summit's core markets sign off. Competing in immuno-oncology also means going up against some of the largest and best-funded pharmaceutical companies in the world.
Investor Outlook
Summit Therapeutics Inc. (SMMT) carries a Weiss Rating of D- (Sell). Today's sell-the-news reaction to positive survival data shows how much of the good news was already in the price. Investors should watch for results from Summit's own U.S. development program, which will determine whether the China-only HARMONi-GI1 findings translate to the markets that matter most for the company's valuation. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--